WHO approves India’s vaccine Covaxin

New Delhi/Hyderabad: The World Health Organisation (WHO) has approved Covaxin, India’s first home-grown vaccine against Covid.

The WHO’s Technical Advisory Group (TAG) granted the Emergency Use Listing (EUL) approval to Bharat Biotech’s Covaxin vaccine, which has demonstrated 77.8 percent effectiveness against symptomatic Covid-19.

The TAG has determined that the Covaxin vaccine meets WHO standards for protection against the Covid pandemic and the benefit of the vaccine far outweighs risks and the vaccine can be used, the WHO said in a tweet.

Developed by Bharat Biotech in partnership with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), Pune, Covaxin is a whole virion-inactivated vaccine.

With validation from the WHO, countries can now expedite their regulatory approval processes to import and administer Covaxin. 

Furthermore, UNICEF, Pan-American Health Organisation (PAHO), GAVI COVAX facility, will be able to procure Covaxin for distribution to countries worldwide, Bharat Biotech said.

This will enable them to secure the critical supply needed to meet the requirements of priority populations, thereby ensuring equitable access, the vaccine maker said.

WHO Director General, Dr Tedros Adhanom Ghebreyesus said: “Glad to see one more vaccine, Covaxin, being granted emergency use listing. The more products we have to fight Covid-19, the better. But we must keep up the pressure to deliver Vaccine Equity and prioritise access to vulnerable groups who are still waiting for their 1st dose.”

Image courtesy of thesatimes

Share this post